Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| SOBR | Sobr Safe | $2.29 | $0.99 | 76.15% | 48.7M | $2.0M | $1.27$14.50 |
| INDP | Indaptus Therapeutics | $2.98 | $1.03 | 52.82% | 16.9M | $3.4M | $1.65$47.60 |
| AFJK | Aimei Health Technology | $64.75 | $20.74 | 47.13% | 3.5K | $269M | $6.75$98.15 |
| DVAX | Dynavax Technologies | $15.46 | $4.33 | 38.86% | 9.8M | $1.3B | $9.20$15.49 |
| EUDA | Euda Health | $2.56 | $0.64 | 33.30% | 907.9K | $73M | $1.03$4.70 |
| ASPC | A Spac III Acquisition Corp. | $21.12 | $5.02 | 31.20% | 68.4K | $38M | $9.95$63.98 |
| IZM | Iczoom Group | $2.29 | $0.49 | 27.39% | 393.7K | $22M | $0.87$2.74 |
| DRMA | Dermata Therapeutics | $2.46 | $0.42 | 20.59% | 17.1M | $2.1M | $1.97$23.70 |
| RPTX | Repare Therapeutics | $2.60 | $0.43 | 19.59% | 11.1M | $94M | $0.89$2.66 |
| SIDU | Sidus Space | $1.93 | $0.28 | 16.97% | 22.4M | $58M | $0.63$6.75 |
Related Articles
Featured Article
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%
George Budwell, PhD|Aug 16, 2023
This small-cap biotech stock holds enormous growth potential.
Could an FDA Approval Send This Stock Flying?
David Jagielski, CPA|Mar 1, 2023
Is now the time to load up on this struggling stock?
Will Valneva and Dynavax Score With Their Late-to-the-Party COVID Vaccine?
Keith Speights and Brian Orelli, PhD|Oct 29, 2021
There's still a sizable market opportunity, especially in developing nations.
Advertisement
How Will Valneva's COVID Vaccine Setback Impact Dynavax?
Keith Speights and Brian Orelli, PhD|Sep 25, 2021
It's definitely not a showstopper for the biotech or its CpG 1018 adjuvant.
2 Biotech Stocks ARK Invest Bought in June
Cory Renauer|Jun 7, 2021
Should you follow Cathie Wood's latest genomic revolution investments?
How Dynavax Demolished Expectations With Its Q1 Results
Keith Speights|May 7, 2021
The company's hepatitis B vaccine wasn't its key growth driver.
Dynavax's Q4 Results Show It's Not Just About Heplisav-B Anymore
Keith Speights|Feb 26, 2021
The company's collaborations and CpG 1018 vaccine adjuvant are playing an increasingly important role.
2 Great Stocks Under $10 a Share
Dave Kovaleski|Jan 28, 2021
One is making a COVID-19 vaccine; the other is a fintech.
4 Reasons Agios' Oncology Deal Should Please Investors
Cory Renauer|Dec 22, 2020
Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.
Why These 3 Coronavirus Vaccine Stocks Plunged in August
John Bromels|Sep 8, 2020
Even these top contenders had a rough end to the summer.
